KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $13.9 million.

  • Recursion Pharmaceuticals' Accounts Payables rose 51659.29% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year increase of 51659.29%. This contributed to the annual value of $21.6 million for FY2024, which is 44674.93% up from last year.
  • Recursion Pharmaceuticals' Accounts Payables amounted to $13.9 million in Q3 2025, which was up 51659.29% from $19.3 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Accounts Payables registered a high of $25.1 million during Q1 2025, and its lowest value of $2.1 million during Q2 2023.
  • In the last 5 years, Recursion Pharmaceuticals' Accounts Payables had a median value of $4.2 million in 2022 and averaged $7.2 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first crashed by 4701.06% in 2024, then soared by 51659.29% in 2025.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Accounts Payables stood at $2.8 million in 2021, then skyrocketed by 62.68% to $4.6 million in 2022, then fell by 13.8% to $4.0 million in 2023, then soared by 446.75% to $21.6 million in 2024, then crashed by 35.52% to $13.9 million in 2025.
  • Its Accounts Payables stands at $13.9 million for Q3 2025, versus $19.3 million for Q2 2025 and $25.1 million for Q1 2025.